NCT04145024 Giessen Pulmonary Hypertension Registry and Biobank
| NCT ID | NCT04145024 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Giessen |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 1993-07 |
| Primary Completion | 2035-07-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 1993-07 with a primary completion date of 2035-07-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Giessen Pulmonary Hypertension Registry and Biobank
Eligibility Criteria
Inclusion Criteria: * Right heart catheterization for PH diagnosis in Giessen Exclusion Criteria: * informed consent missing
Contact & Investigator
Khodr Tello, MD
PRINCIPAL INVESTIGATOR
University Clinics of Giessen and Marburg
Frequently Asked Questions
Who can join the NCT04145024 clinical trial?
This trial is open to participants of all sexes, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04145024 currently recruiting?
Yes, NCT04145024 is actively recruiting participants. Contact the research team at khodr.tello@innere.med.uni-giessen.de for enrollment information.
Where is the NCT04145024 trial being conducted?
This trial is being conducted at Giessen, Germany.
Who is sponsoring the NCT04145024 clinical trial?
NCT04145024 is sponsored by University of Giessen. The principal investigator is Khodr Tello, MD at University Clinics of Giessen and Marburg. The trial plans to enroll 10,000 participants.